1 Biotech Maximizing Shareholder Value
The following video is part of our "Motley Fool Conversations" series, in which health-care editor/analyst David Williamson and consumer goods editor/analyst Austin Smith discuss topics across the investing world.
In today's edition, David and Austin discuss Amylin's recent alleged rejection of Bristol-Myer's buyout offer and the events that have happened since. Big pharma has been on the hunt recently, snapping up assets and restocking pipelines to mitigate the damage from the patent cliff. David and Austin catch viewers up on why Amylin is an attractive asset, why Carl Icahn is feeling better, and which big pharma companies Amylin could tie the knot with.
Health-care investors are always looking for the next big breakthrough. Motley Fool co-founder David Gardner recently identified a small-cap health-care company that he believes is poised for monster returns. To uncover this top pick today, enjoy the special free report: "Discover the Next Rule-Breaking Multibagger." Don't miss out on this limited-time offer and your opportunity to discover this game-changing company before the market does. Click here to access your report -- it's totally free.
At the time this article was published Austin Smith has no positions in the stocks mentioned above. David Williamson has no positions in the stocks mentioned above. The Motley Fool owns shares of AstraZeneca. Try any of our Foolish newsletter servicesfree for 30 days. We Fools may not all hold the same opinions, but we all believe thatconsidering a diverse range of insightsmakes us better investors. The Motley Fool has adisclosure policy.